Terns Pharmaceuticals, Inc. Non-operating Income/Expense

Non-operating Income/Expense of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.


Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending March 31, 2022 was $73 Thousand (a 630.0% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense increased by 87.18%
  • Annual Non-operating Income/Expense for 2021 was $40 Thousand (a -98.66% decrease from previous year)
  • Annual Non-operating Income/Expense for 2020 was $2.99 Million (a 1838.96% increase from previous year)
  • Annual Non-operating Income/Expense for 2019 was $154 Thousand (a 305.26% increase from previous year)
  • Twelve month Non-operating Income/Expense ending March 31, 2022 was $126 Thousand (a 215.0% increase compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense decreased by -105.9% year-over-year
Trailing Non-operating Income/Expense for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$126 Thousand $40 Thousand $620 Thousand $-2.14 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of Terns Pharmaceuticals, Inc.

Most recent Non-operating Income/Expenseof TERN including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.07
2021 $0.01 $0.0 $0.04 $-0.01 $0.04
2020 $0.59 $-2.75 $0.25 $0.22 $2.99
2019 $0.14 $0.15
2018 $0.04

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.